Spruce Biosciences SPRB 深 沪
等待开盘 09-17 09:30:00 美东时间
54.16
-1.005
-1.82%
华盛通- 最 高56.27
- 今 开55.01
- 成交量 10.03万股
- 最 低 53.26
- 昨 收 55.165
- 总市值 1.56亿
- 52周最高 240.00
- 市盈率 静 --
- 换手率 3.49%
- 52周最低 7.26
- 委 比 42.86%
- 总股本 287.40万
- 历史最高 240.00
- 量 比 0.97
- 振 幅 5.46%
- 历史最低 7.26
- 每 手 1
- 风险率 31.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-26 18:20
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $150 to $144.
08-13 21:58
Spruce Biosciences GAAP EPS of -$6.68
Spruce Biosciences press release (SPRB): Q2 GAAP EPS of -$6.68. Cash and cash equivalents as of June 30, 2026 were $96.3 million, compared to $48.9 million as of December 31, 2025. Spruce believes tha...
08-12 21:05
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. Q2 EPS $(6.68) Misses $(5.80) Estimate
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(6.68) per share which missed the analyst consensus estimate of $(5.80) by 15.17 percent. This is a 90.86 percent decrease over losses of $(3.50) per share from the same period last year.
08-12 21:03
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
B. Riley Securities Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $160
B. Riley Securities analyst Madison El-Saadi initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $160.
07-13 21:07
美股大行评级 | 潜在涨幅117.92%！摩根大通上调Camp4 Therapeutics目标价至9美元，维持"超配"评级
今日重点评级关注：摩根大通：上调Camp4 Therapeutics评级至"超配"，目标价从5美元升至9美元；Canaccord Genuity：维持Rhythm制药"买入"评级，目标价从143美元升至151美元
06-17 11:32
Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $123.
06-16 20:32
